Based on this study, Matthew et al. further confirmed that first-line treatment with nivolumab plus ipilimumab resulted in a longer duration of OS than did chemotherapy in NSCLC patients, independent of their PD-L1 expression level (CheckMate 227) [58]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.